Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 extension study in sporadic inclusion body myositis
NL-OMON42420Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of bimagrumab in sporadic inclusion body myositis (sIBM) (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of different intravenous BYM338 doses and Change from baseline in 6 Minute Walking Distance Test. Started Nov 2015; status: active, not recruiting.
02
Drugs
bimagrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NL-OMON42420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42420.